BR1400-2
Phase 2Small molecule
Boryung Pharmaceutical Co., LtdBR1400-2 is one of 26 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
51 competitors in Essential Hypertension
#DrugCompanyPhaseTrials
1Zebeta
TevaApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Bayer Aspirin
BayerApproved
Rifadin
SanofiApproved
Cialis
Eli LillyApproved
Aldactone
PfizerApproved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cardura
VViatris Specialty LLC
Approved
Nizoral
WWim Janssens
Approved
Coreg
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BR1400-2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details